<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02256189</url>
  </required_header>
  <id_info>
    <org_study_id>300A</org_study_id>
    <nct_id>NCT02256189</nct_id>
  </id_info>
  <brief_title>Sitagliptin and Glucagon Counterregulation</brief_title>
  <acronym>SITACLAMP</acronym>
  <official_title>The Effect of Sitagliptin on Glucagon Counterregulation and Incretin Hormones During Mild Hypoglycemia in Elderly Patients With Metformin-treated Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lund University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect of DPP-4 inhibition on glucagon counter-regulatory mechanisms at
      moderate hypoglycemia in metformin-treated subjects with T2DM
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The glucagon response to mild (3.0 mmol/l) hypoglycemia with and without DPP-4 inhibition by
      sitagliptin will be evaluated in elderly subjects with metformin treated type 2 diabetes to
      explore whether DPP-4 inhibition affects glucagon counter-regulation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucagon counterregulation to hypoglycemia</measure>
    <time_frame>Six weeks treatment</time_frame>
    <description>Increase in plasma glucagon to insulin-induced hypoglycemia after six weeks of treatment with sitagliptin and placebo</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hypoglycemia clamp with sitagliptin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Hypoglycemia clamp with placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Treatment with sitagliptin 100mg QD for four weeks followed by hyperinsulinemic hypoglycemic clamp</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <other_name>Activa comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Treatment with placebo QD for four weeks followed by hyperinsulinemic hypoglycemic clamp</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written consent has been given.

          2. Patients with metformin treated T2DM (metformin dose &gt;0,5 g/day and stable during the
             preceding 3 months)

          3. Age &gt;65 years.

          4. HbA1c 6.0-8.5% (43-67 mmol/mol; inclusive) at visit 1.

          5. Ability to complete the study

        Exclusion Criteria:

          1. A history of any secondary forms of diabetes, e.g., Cushing's syndrome and acromegaly.

          2. Type 2 diabetes, positive GAD antibodies

          3. eGFR &lt;60 ml/min

          4. Acute infections which may affect blood glucose control within 4 weeks prior to visit
             1

          5. Any history of recent (&lt;2 weeks) recurrent or severe hypoglycemic episodes.

          6. Liver disease such as cirrhosis or chronic active hepatitis

          7. History of coronary heart disease or heart failure class III or IV

          8. Donation of one unit (500 ml) or more of blood, significant blood loss equaling to at
             least one unit of blood within the past 2 weeks or a blood transfusion within the past
             8 weeks.

          9. Treatment with growth hormone of chronic oral or parenteral corticosteroid treatment
             (&gt; 7 consecutive days of treatment) within 8 weeks prior to visit 1.

         10. Use of other investigational drugs at visit 1 or within 30 days of visit 1, unsuitable
             for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo Ahrén, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skane University Hospital Malmö</name>
      <address>
        <city>Malmö</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2014</study_first_submitted>
  <study_first_submitted_qc>September 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2014</study_first_posted>
  <last_update_submitted>July 19, 2017</last_update_submitted>
  <last_update_submitted_qc>July 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lund University</investigator_affiliation>
    <investigator_full_name>Bo Ahren</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Glucagon</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 18, 2017</submitted>
    <returned>December 14, 2017</returned>
    <submitted>December 18, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

